Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on developing precision therapies for solid tumors, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's CEO, Elisabet de los Pinos, PhD, will deliver a presentation on September 10, 2025, at 11:00 a.m. ET. Investors can access the live webcast through Aura's investor relations website, where it will remain available for replay for 90 days after the presentation.
Aura Biosciences (NASDAQ: AURA), azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie mirate per tumori solidi, ha comunicato la sua partecipazione al 27掳 Annual Global Investment Conference di H.C. Wainwright.
La CEO, Elisabet de los Pinos, PhD, terr脿 una presentazione il 10 settembre 2025 alle 11:00 ET. Gli investitori potranno seguire la diretta via webcast sul sito investor relations di Aura; la registrazione rester脿 disponibile per la visione on demand per 90 giorni dopo l'evento.
Aura Biosciences (NASDAQ: AURA), compa帽铆a biotecnol贸gica en fase cl铆nica dedicada al desarrollo de terapias de precisi贸n para tumores s贸lidos, ha anunciado su participaci贸n en la 27.陋 Conferencia Global Anual de Inversi贸n de H.C. Wainwright.
La directora ejecutiva, Elisabet de los Pinos, PhD, ofrecer谩 una presentaci贸n el 10 de septiembre de 2025 a las 11:00 a.m. ET. Los inversores podr谩n ver la transmisi贸n en directo a trav茅s de la web de relaciones con inversores de Aura; la grabaci贸n estar谩 disponible para reproducci贸n durante 90 d铆as tras la presentaci贸n.
Aura Biosciences (NASDAQ: AURA), 瓿犿槙膦呾枒鞚� 鞙勴暅 鞝曤皜 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厡韥� 旮办梾鞚� H.C. Wainwright 鞝�27須� 鞐半 旮�搿滊矊 韴瀽 旖橅嵓霟办姢鞐� 彀戈岸捻暅雼り碃 氚滍憸頄堨姷雼堧嫟.
CEO Elisabet de los Pinos, PhD臧赌 2025雲� 9鞗� 10鞚� 鞓れ爠 11:00(霃欕秬鞁滉皠)鞐� 氚滍憸毳� 歆勴枆頃╇媹雼�. 韴瀽鞛愲摛鞚� Aura鞚� 韴瀽鞛愱磤瓿� 鞗轨偓鞚错姼鞐愳劀 鞁れ嫓臧� 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 氚滍憸 頉� 90鞚缄皠 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
Aura Biosciences (NASDAQ: AURA), soci茅t茅 biotechnologique en phase clinique d茅di茅e au d茅veloppement de th茅rapies cibl茅es pour tumeurs solides, a annonc茅 sa participation 脿 la 27e conf茅rence mondiale annuelle sur l'investissement de H.C. Wainwright.
La directrice g茅n茅rale, Elisabet de los Pinos, PhD, prononcera une pr茅sentation le 10 septembre 2025 脿 11h00 ET. Les investisseurs pourront suivre la retransmission en direct via le site relations investisseurs d'Aura ; l'enregistrement restera disponible en replay pendant 90 jours apr猫s la pr茅sentation.
Aura Biosciences (NASDAQ: AURA), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung pr盲ziser Therapien f眉r solide Tumoren spezialisiert hat, hat seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference 补苍驳别办眉苍诲颈驳迟.
Die Gesch盲ftsf眉hrerin, Elisabet de los Pinos, PhD, wird am 10. September 2025 um 11:00 Uhr ET eine Pr盲sentation halten. Investoren k枚nnen das Live-Webcast 眉ber die Investor-Relations-Website von Aura verfolgen; die Aufzeichnung steht 90 Tage nach der Pr盲sentation zum Abruf bereit.
- None.
- None.
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 听(狈础厂顿础蚕: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today聽announced that聽Elisabet de聽los Pinos, PhD, Chief Executive Officer, will present at the聽H.C. Wainwright 27th Annual Global Investment Conference on聽Wednesday, September 10, 2025, at 11:00 a.m. ET.
The live webcast of the presentation will be available on the 鈥淚nvestors & Media鈥� page under the 鈥淓vents & Presentations鈥� section of the Company鈥檚 website at聽, where a replay of the webcast will be archived for 90 days following the presentation date.
About聽Aura Biosciences
Aura Biosciences聽is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer.聽Aura Biosciences聽is headquartered in聽Boston, MA.聽Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
For more information, visit聽. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.
Investor and Media Relations Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
FAQ
When is Aura Biosciences (AURA) presenting at the H.C. Wainwright Conference?
Who will represent Aura Biosciences at the H.C. Wainwright Conference?
How can investors access Aura Biosciences' H.C. Wainwright Conference presentation?
What type of company is Aura Biosciences (AURA)?
